PIN-5018 / Pin Therap - LARVOL DELTA

Next trip: a promising CK1α-selective molecular glue degrader in MSS colorectal cancer (AACR 2025) - "We recently developed PIN5018, a selective CK1α inhibitor, and reported that it exhibits promising anticancer activity in acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC)...Taken together, these findings demonstrate the potential of our CK1α-selective MGD as a promising therapeutic candidate not only for AML and ACC but also for MSS CRC. Lastly, we are aiming for clinical entry by 2025 Q1."

Acute Myelogenous Leukemia • Adenoid Cystic Carcinoma • Colorectal Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Pintherapeutics succeeds in raising 20 billion won in Series C amid bio-cold season [Google translation] (Hankyung) - "Pin Therapeutics, a protein degradation (TPD) drug development company, announced on the 23rd that it had attracted approximately KRW 20 billion in Series C investment....Through this investment, Pin Therapeutics plans to receive IND approval in the US and Korea in 2025 and advance its lead pipeline, a CK1α-selective degrader (PIN-5018), into the clinical stage. It also plans to discover additional next-generation pipelines based on platform technology."

Financing • IND • New trial • Oncology • Solid Tumor